Marie Bosslett, Assistant Editor

Explore real-world strategies with Leigh Ann Pansch, MSN, FNP-BC, DCNP, for managing psoriasis, emphasizing patient-centered care, and implementing individualized biologic treatment approaches.

Medicus Pharma has initiated a phase 2 trial in the United Arab Emirates (UAE), exploring noninvasive treatment for basal cell carcinoma (BCC) using innovative microneedle technology.

Discover non-clinical career paths for PAs and NPs at the 2025 PDPA Keystone Conference, featuring insights from Shanna Miranti, MPAS, PA-C, and Lauren Miller, PA-C.

CO₂ laser treatment significantly enhances quality of life for hidradenitis suppurativa patients, showing promising outcomes in a large prospective study.

Cemiplimab is revolutionizing treatment for high-risk cutaneous squamous cell carcinoma, bridging gaps in care and improving patient outcomes.

Azitra reveals promising preclinical results for ATR-01, a novel treatment targeting ichthyosis vulgaris, paving the way for future clinical trials.

Experts discuss the OX40 pathway's potential to transform atopic dermatitis treatment, addressing unmet needs and promising new therapies for better patient outcomes.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news about the approval of cemiplimab as adjuvant immunotherapy for high-risk CSCC, FDA safety communication on RF microneedling, dermatologists' role in breast cancer awareness, and more.

This review of the latest dermatologic studies highlights new research on hidradenitis suppurativa, including associated pediatric comorbidities, CO2 laser treatment, impact on sexual health, and more.

Vishal A. Patel, MD, discusses cemiplimab's FDA approval as a groundbreaking adjuvant therapy for high-risk cutaneous squamous cell carcinoma patients.

FDA warns of serious risks associated with RF microneedling, urging patient education and careful provider training to ensure safety in aesthetic dermatology.

Mobile app SkinTracker enhances atopic dermatitis care through remote assessments, proving effective and convenient for patients while saving costs.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.

Kachiu Lee, MD, MPH, FAAD, shares insights on aesthetic dermatology at the 2025 PDPA Keystone, emphasizing trust and communication over technology for optimal results.

A novel 4% glycyrrhetinic acid scalp gel shows rapid relief for mild to moderate seborrheic dermatitis, enhancing treatment options with herbal ingredients.

Topical dapsone shows promise in treating various mucocutaneous diseases, including rosacea and neutrophilic dermatoses, with a favorable safety profile.

Regeneron's cemiplimab-rwlc gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, significantly improving disease-free survival.

Explore the latest advancements in retinoid technology with AlphaRet, enhancing skin tolerability and efficacy for diverse patient needs.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news about roflumilast's expanded access for children as young as 2, LP-10 for oral lichen planus, SYX-5219's IND clearance, and more.

Amy Lewis, MD, integrates Glo2Facial into her practice to enhance patient relationships and promote early skin health through innovative aesthetic treatments.

A study reveals ixekizumab's effectiveness in treating mild to moderate plaque psoriasis, showing superior PASI responses and improved long-term outcomes.

Discover how the Glo2Facial revolutionizes aesthetic dermatology with innovative skin oxygenation and customizable treatments for radiant, youthful skin.

New research highlights the psychosocial impact of rosacea on Chinese patients, linking lifestyle factors and comorbidities to quality of life.

Explore real-world psoriasis management insights from Anthony Nuara, MD, PhD, focusing on patient-centered approaches and innovative treatments like tildrakizumab.

A new trial reveals that combining Excimer laser with JAK inhibitors significantly enhances vitiligo treatment outcomes, ensuring safety and durability.

This review of the latest dermatologic studies highlights new research on mitigating irritation from 0.1% retinol, OTC therapies for alopecia, the perception of skin lesions by HCPs in the delivery room, and more.

New research highlights the link between isotretinoin dosage and increased chronic hand eczema, emphasizing the need for careful monitoring during acne treatment.

Lipella Pharmaceuticals' LP-10 shows promise as a targeted treatment for OLP, offering safety and efficacy in recent trials, according to Michael Chancellor, MD.